Liaoning He Eye Hospital Group (301103.SZ) issues a profit warning, expecting a net loss of 20.5 million to 30.75 million yuan in 2024, turning from profit to loss.
He Medical Ophthalmology (301103.SZ) released the 2024 annual performance forecast, with the company expecting...
Liaoning He Eye Hospital Group (301103.SZ) released the performance forecast for the year 2024, with the company expecting a net loss attributable to shareholders of the listed company of 20.5 million yuan to 30.75 million yuan, a switch from profit to loss; a net loss of 22 million yuan to 32.5 million yuan after deducting non-recurring gains and losses, also a switch from profit to loss.
During the reporting period, intensified industry competition and the impact of healthcare payment reform caused a decrease in the company's revenue and gross profit. The company has invested heavily in innovative business, digitalization, and R&D projects, resulting in increased cost and expense compared to the same period last year.
Related Articles

US Stock Market Move | Taiwan liquor merchant Agencia Comercial Spirits (AGCC.US) landed on the US stock market, opening with a rise of over 4.7%.

US Stock Market Move | Net Plastic Technology (NPT.US) debuts on the US stock market, triggering a circuit breaker after the opening.

US Stock Market Move | Chip stocks generally fell, with Intel Corporation (INTC.US) falling over 4%.
US Stock Market Move | Taiwan liquor merchant Agencia Comercial Spirits (AGCC.US) landed on the US stock market, opening with a rise of over 4.7%.

US Stock Market Move | Net Plastic Technology (NPT.US) debuts on the US stock market, triggering a circuit breaker after the opening.

US Stock Market Move | Chip stocks generally fell, with Intel Corporation (INTC.US) falling over 4%.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025